ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PRM Proteome Sciences Plc

3.39
0.09 (2.73%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Proteome Sciences Plc LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.09 2.73% 3.39 3.00 3.78 17,740 16:35:09
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 7.78M 1.33M 0.0045 7.33 9.74M

Proteome Sciences PLC Appointment of Nominated Adviser and Broker (0381L)

20/12/2018 7:01am

UK Regulatory


Proteome Sciences (LSE:PRM)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Proteome Sciences Charts.

TIDMPRM

RNS Number : 0381L

Proteome Sciences PLC

20 December 2018

20 December 2018

Proteome Sciences plc

(the "Company")

Appointment of Nominated Adviser and Broker

The Board of Proteome Sciences plc is pleased to announce that Allenby Capital Limited has been appointed as the Company's new Nominated Adviser and sole Broker with immediate effect.

For further information please contact:

 
 Proteome Sciences plc 
 Dr Jeremy Haigh, Chief Executive Officer    Tel: +44 (0)20 7043 2116 
 Dr Ian Pike, Chief Scientific Officer 
  Richard Dennis, Chief Commercial Officer 
 
 Allenby Capital Limited (Nominated Adviser & Broker) 
 John Depasquale / Jeremy Porter             Tel: +44 (0) 20 3328 5656 
 

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant(R) and TMT(R)MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator(TM) provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPTLBRTMBTBBJP

(END) Dow Jones Newswires

December 20, 2018 02:01 ET (07:01 GMT)

1 Year Proteome Sciences Chart

1 Year Proteome Sciences Chart

1 Month Proteome Sciences Chart

1 Month Proteome Sciences Chart

Your Recent History

Delayed Upgrade Clock